ArticleChirality2020
Development of near-infrared firefly luciferin analogue reacted with wild-type and mutant luciferases.
Article in Chirality, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Brighter NIR Bioluminescence System for Mammalian Cell Bioimaging Based on Engineered Railroadworm Luciferase and 6'-Aminoluciferin Analogues.Chemical & biomedical imaging · 2026Article
- Expedient Synthesis and Characterization of π-Extended Luciferins.The Journal of organic chemistry · 2024Article
- In vivo optical imaging of tumor stromal cells with hypoxia-inducible factor activity.Cancer science · 2023Article
- Advances in luminescence-based technologies for drug discovery.Expert opinion on drug discovery · 2023Review
- The Role of Optical Imaging in Translational Nanomedicine.Journal of functional biomaterials · 2022Review
- How to Select Firefly Luciferin Analogues for In Vivo Imaging.International journal of molecular sciences · 2021Review
- Bioluminescent Imaging Systems for Assay Developments.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2021Review
- A Very Bright Far-Red Bioluminescence Emitting Combination Based on Engineered Railroad Worm Luciferase and 6'-Amino-Analogs for Bioimaging Purposes.International journal of molecular sciences · 2020Article
- High Sensitivity In Vivo Imaging of Cancer Metastasis Using a Near-Infrared Luciferin Analogue seMpai.International journal of molecular sciences · 2020Article
- Development of near-infrared firefly luciferin analogue reacted with wild-type and mutant luciferases.Chirality · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Interestingly, only the D-form of firefly luciferin produces light by luciferin-luciferase (L-L) reaction. Certain firefly luciferin analogues with modified structures maintain bioluminescence (BL) activity; however, all L-form luciferin analogues show no BL activity. To this date, our group has developed luciferin analogues with moderate BL activity that produce light of various wavelengths. For in vivo bioluminescence imaging, one of the important factors for detection sensitivity is tissue permeability of the number of photons emitted by L-L reaction, and the wavelengths of light in the near-infrared (NIR) range (700-900 nm) are most appropriate for the purpose. Some NIR luciferin analogues by us had performance for in vivo experiments to make it possible to detect photons from deep target tissues in mice with high sensitivity, whereas only a few of them can produce NIR light by the L-L reactions with wild-type luciferase and/or mutant luciferase. Based on the structure-activity relationships, we designed and synthesized here a luciferin analogue with the 5-allyl-6-dimethylamino-2-naphthylethenyl moiety. This analogue exhibited NIR BL emissions with wild-type luciferase (λ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.